Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trandolapril + verapamil
- Development stage
- Phase 4
- Lead developer
- Abbott
- Modality
- Small Molecules, Drug Delivery Systems
- Administration
- Oral
01
Overview
Trandolapril + verapamil is a fixed-dose combination medication used to treat high blood pressure (hypertension) in adults. It combines two antihypertensive agents with complementary mechanisms of action: - **Trandolapril** is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to relaxation of blood vessels, reduced vascular resistance, and lower blood pressure. - **Verapamil** is a non-dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into cardiac and vascular smooth muscle cells via L-type calcium channels. This results in vasodilation, decreased myocardial contractility, slowed atrioventricular conduction, and further reduction in blood pressure. The combination provides greater antihypertensive efficacy than either agent alone and may offer additional cardiovascular protection for certain patients. The product was marketed under the brand name Tarka as extended-release oral tablets but generic versions remain available[1][2][3][4][5].
- Brand names
- Tarka
- Other names
- trandolapril/verapamiltrandolapril and verapamiltrandolapril-verapamil
02
Targets
ACE (Angiotensin Converting Enzyme)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on trandolapril + verapamil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trandolapril + verapamil.